The DOI matches its Crossref record; 300 of the 302 references it cites were found in a registry or an index.
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Open accessAbstract
The T lymphocyte, especially its capacity for antigen-directed cytotoxicity, has become a central focus for engaging the immune system in the fight against cancer. Basic science discoveries elucidating the molecular and cellular biology of the T cell have led to new strategies in this fight, including checkpoint blockade, adoptive cellular therapy and cancer vaccinology. This area of immunological research has been highly active for the past 50 years and is now enjoying unprecedented bench-to-bedside clinical success. Here, we provide a comprehensive historical and biological perspective regarding the advent and clinical implementation of cancer immunotherapeutics, with an emphasis on the fundamental importance of T lymphocyte regulation. We highlight clinical trials that demonstrate therapeutic efficacy and toxicities associated with each class of drug. Finally, we summarize emerging therapies and emphasize the yet to be elucidated questions and future promise within the field of cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Conversely, myeloid-specific overexpression of HIF-1α results in hyperinflammatory, M1-polarized macrophages associated with increased glycolysis, suggesting a link between HIF-1α and M1-polarization [63].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [63]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The possible contribution of the adaptive immune system in AD patients to reducing cancer incidence has not been studied (4,5).”
From Alzheimer's Disease–Associated Amyloid-β Precursor Protein Prevents Aging Stress–Induced Mitophagy and Fumarate Depletion to Improve Antitumor Immunity (2025) · cites this paper as [5]
Experimental — accuracy not yet measuredIn the citing paper
“Typically, PD‐L1 or PD‐L2 are expressed on the surface of cancer cells or antigen‐presenting cells and transduce a signal for cooperation with PD‐1 expression on the cell surface of T lymphocytes to stimulate restraint signaling [272, 273].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [272]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Cited by
Sorted by citations
Items 301–400 of 1,006
Gao, H., Xi, Z., Dai, J., Xue, J., Guan, X., Zhao, L., Chen, Z., & Xing, F. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02005-y · Cited by 81
Guimarães, G. R., Maklouf, G. R., Teixeira, C. E., Santos, L. D. O., Tessarollo, N. G., de Toledo, N. E., Serain, A. F., de Lanna, C. A., Pretti, M. A. M., da Cruz, J. G. V., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49916-4 · Cited by 93
The diversity of CD8+ T cell dysfunction in cancer and viral infection
Galluzzi, L., Smith, K. N., Liston, A., & Garg, A. D. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-025-01161-6 · Cited by 94
Macrophages and Extracellular Matrix in Breast Cancer: Partners in Crime or Protective Allies?
Deligne, C., & Midwood, K. S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.620773 · Cited by 84
Fakharian, F., Asgari, B., Nabavi-Rad, A., Sadeghi, A., Soleimani, N., Yadegar, A., & Zali, M. R. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.953718 · Cited by 79
T-cell repertoire diversity: friend or foe for protective antitumor response?
Porciello, N., Franzese, O., D’Ambrosio, L., Palermo, B., & Nisticò, P. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02566-0 · Cited by 88
Antigen Presenting Cell Mimetic Lipid Nanoparticles for Rapid mRNA CAR T Cell Cancer Immunotherapy
Metzloff, A. E., Padilla, M. S., Gong, N., Billingsley, M. M., Han, X., Merolle, M. I., Mai, D., Figueroa‐Espada, C. G., Thatte, A. S., Haley, R. M., et al. (2024) · Advanced Materials · doi:10.1002/adma.202313226 · Cited by 82
The evolving landscape of tissue‐agnostic therapies in precision oncology
Subbiah, V., Gouda, M. A., Ryll, B., Burris, H. A., & Kurzrock, R. (2024) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21844 · Cited by 88
Krishnamoorthy, M., Lenehan, J. G., & Vareki, S. M. (2020) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaa216 · Cited by 75
Advanced Flow Cytometry Assays for Immune Monitoring of CAR-T Cell Applications
Blache, U., Weiss, R., Boldt, A., Kapinsky, M., Blaudszun, A., Quaiser, A., Pohl, A., Miloud, T., Burgaud, M., Vučinić, V., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.658314 · Cited by 81
The role of CD71+ erythroid cells in the regulation of the immune response
Grzywa, T. M., Nowis, D., & Gołąb, J. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107927 · Cited by 81
Combining Cancer Vaccines with Immunotherapy: Establishing a New Immunological Approach
Kim, C.-G., Sang, Y. B., Lee, J. H., & Chon, H. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158035 · Cited by 78
Virus-like Particles as Preventive and Therapeutic Cancer Vaccines
Tornesello, A. L., Tagliamonte, M., Buonaguro, F. M., Tornesello, M. L., & Buonaguro, L. (2022) · Vaccines · doi:10.3390/vaccines10020227 · Cited by 76
Takacs, G. P., Kreiger, C. J., Luo, D., Tian, G., Garcia, J. S., Deleyrolle, L. P., Mitchell, D. A., & Harrison, J. K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.993444 · Cited by 73
Ou, W., Stewart, S., White, A. M., Kwizera, E. A., Xu, J., Fang, Y., Shamul, J. G., Xie, C., Nurudeen, S. M., Tirada, N. P., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36045-7 · Cited by 78
Varveri, A., Papadopoulou, M., Papadovasilakis, Z., Compeer, E. B., Legaki, A., Delis, A. D., Damaskou, V., Boon, L., Papadogiorgaki, S., Samiotaki, M. K., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49282-1 · Cited by 80
Blebbisomes are large, organelle-rich extracellular vesicles with cell-like properties
Jeppesen, D. K., Sanchez, Z., Kelley, N. M., Hayes, J. B., Ambroise, J., Koory, E., Krystofiak, E., Taneja, N., Zhang, Q., Dungan, M. M., et al. (2025) · Nature Cell Biology · doi:10.1038/s41556-025-01621-0 · Cited by 88
VDAC2 loss elicits tumour destruction and inflammation for cancer therapy
Yuan, S., Sun, R., Shi, H., Chapman, N. M., Hu, H., Guy, C. S., Rankin, S. L., Anil, K. C., Palacios, G., Meng, X., et al. (2025) · Nature · doi:10.1038/s41586-025-08732-6 · Cited by 82
Naik, A., & Decock, J. V. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.598626 · Cited by 82
Nanomedicine-based cancer immunotherapy: recent trends and future perspectives
Lakshmanan, V., Jindal, S., Packirisamy, G., Ojha, S. K., Lian, S., Kaushik, A. K., Alzarooni, A. I. M. A., Metwally, Y. H. H., Thyagarajan, S. P., Jung, Y. D., et al. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-021-00299-4 · Cited by 78
Targeting loss of heterozygosity for cancer-specific immunotherapy
Hwang, M. S., Mog, B. J., Douglass, J., Pearlman, A. H., Hsiue, E. H.-C., Paul, S., DiNapoli, S. R., Konig, M. F., Pardoll, D. M., Gabelli, S. B., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2022410118 · Cited by 80
Emerging Trends in Immunotherapy for Cancer
Mishra, A., Ali, A., Dutta, S., Banday, S., & Malonia, S. K. (2022) · Diseases · doi:10.3390/diseases10030060 · Cited by 79
Liposomes for the Treatment of Brain Cancer—A Review
Raju, R., Abuwatfa, W. H., Pitt, W. G., & Husseini, G. A. (2023) · Pharmaceuticals · doi:10.3390/ph16081056 · Cited by 82
Magnetic systems for cancer immunotherapy
Day, N. B., Wixson, W. C., & Shields, C. W. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.03.023 · Cited by 79
Targeting TIGIT for Immunotherapy of Cancer: Update on Clinical Development
Rotte, A., Sahasranaman, S., & Budha, N. R. (2021) · Biomedicines · doi:10.3390/biomedicines9091277 · Cited by 79
Bonté, P., Arribas, Y. A., Merlotti, A., Carrascal, M., Zhang, J. V., Zueva, E., Binder, Z. A., Alanio, C., Goudot, C., & Amigorena, S. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110916 · Cited by 81
Tsai, Y., Ko, C.-A., Chen, H., Hsu, C., Lai, C., Lee, Y., Tsai, M., Chang, G., Huang, E. I., & Fang, K. (2022) · Journal of Cancer · doi:10.7150/jca.74930 · Cited by 77
Artificial Antigen-Presenting Cell Topology Dictates T Cell Activation
Wauters, A. C., Scheerstra, J. F., Vermeijlen, I. G., Hammink, R., Schluck, M., Woythe, L., Wu, H., Albertazzi, L., Figdor, C. G., Tel, J., et al. (2022) · ACS Nano · doi:10.1021/acsnano.2c06211 · Cited by 75
SHP2 deneddylation mediates tumor immunosuppression in colon cancer via the CD47/SIRPα axis
Li, Y., Zhou, H., Liu, P., Lv, D., Shi, Y., Tang, B., Xu, J., Zhong, T., Xu, W., Zhang, J., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci162870 · Cited by 79
Wang, Y., Liu, B., Min, Q., Yang, X., Yan, S., Ma, Y., Li, S., Fan, J., Wang, Y., Dong, B., et al. (2023) · Cell Discovery · doi:10.1038/s41421-023-00591-7 · Cited by 82
Sequential immunotherapy: towards cures for autoimmunity
Ramírez‐Valle, F., Maranville, J., Roy, S., & Plenge, R. M. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00959-8 · Cited by 81
Watson, R. A., Tong, O., Cooper, R. A., Taylor, C. A., Sharma, P. K., Aires, A. V. D. L., Mahé, E. A., Ruffieux, H., Nassiri, I., Middleton, M. R., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abj8825 · Cited by 76
Song, Z., Liu, B., Peng, X., Gu, W., Sun, Y., Xing, L., Xu, Y., Geng, M., Ai, J., & Zhang, A. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01422 · Cited by 74
Huang, D., Wu, T. S., Lan, S., Liu, C., Guo, Z., & Zhang, W. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121808 · Cited by 75
Engineering Human MAIT Cells with Chimeric Antigen Receptors for Cancer Immunotherapy
Dogan, M., Karhan, E., Kozhaya, L., Placek, L., Chen, X., Yiğit, M., & Unutmaz, D. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2100856 · Cited by 78
Nanocarriers for cancer nano-immunotherapy
Rana, I., Oh, J., Baig, J., Moon, J. H., Son, S., & Nam, J. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-022-01241-3 · Cited by 76
T Cell Based Immunotherapy for Cancer: Approaches and Strategies
Want, M. Y., Bashir, Z., & Najar, R. A. (2023) · Vaccines · doi:10.3390/vaccines11040835 · Cited by 79
IL-2-driven CD8+ T cell phenotypes: implications for immunotherapy
Niederlová, V., Tsyklauri, O., Kovář, M., & Štěpánek, O. (2023) · Trends in Immunology · doi:10.1016/j.it.2023.09.003 · Cited by 78
Liposome-integrated hydrogel hybrids: Promising platforms for cancer therapy and tissue regeneration
Sanati, M., & Yavari, S. A. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.03.008 · Cited by 77
Jha, B. S., Farnoodian, M., & Bharti, K. (2020) · Stem Cells Translational Medicine · doi:10.1002/sctm.20-0242 · Cited by 73
Immunotherapies for hepatocellular carcinoma
Liu, J. K. H., Irvine, A. F., Jones, R. L., & Samson, A. (2021) · Cancer Medicine · doi:10.1002/cam4.4468 · Cited by 72
Innovation in cancer therapeutics and regulatory perspectives
Sharma, P., Jhawat, V., Mathur, P., & Dutt, R. (2022) · Medical Oncology · doi:10.1007/s12032-022-01677-0 · Cited by 76
Kamal, N., Ilowefah, M. A., Hilles, A. R., Anua, N. A., Awin, T. M., Alshwyeh, H. A., Aldosary, S. K., Sahib, N. G., Alosaimi, A. A., Rahman, A., et al. (2022) · Molecules · doi:10.3390/molecules27061794 · Cited by 79
Immunotherapy of glioblastoma: Recent advances and future prospects
Yuan, B., Wang, G., Tang, X., Tong, A., & Zhou, L. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2055417 · Cited by 77
Qayoom, H., Sofi, S., & Mir, M. A. (2023) · Immunologic Research · doi:10.1007/s12026-023-09376-2 · Cited by 74
Wang, Y., Shi, J., Xin, M., Kahkoska, A. R., Wang, J., & Gu, Z. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01230-6 · Cited by 82
Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer
Hsieh, C.-H., Jian, C.-Z., Lin, L., Low, G.-S., Ou, P.-Y., Hsu, C., & Ou, D. (2022) · Cancers · doi:10.3390/cancers14020294 · Cited by 70
Jiang, J., Wang, Y., Gao, Y., Sugimura, H., Minervini, F., Uchino, J., Halmos, B., Yendamuri, S., Velotta, J. B., & Li, M. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-75 · Cited by 73
Hasan, M. N., Capuk, O., Patel, S. M., & Sun, D. (2022) · Cancers · doi:10.3390/cancers14143331 · Cited by 75
Monocyte-neutrophil entanglement in glioblastoma
Friedmann‐Morvinski, D., & Hambardzumyan, D. (2023) · Journal of Clinical Investigation · doi:10.1172/jci163451 · Cited by 71
Research Progress of Nanomedicine-Based Mild Photothermal Therapy in Tumor
He, X., Zhang, S., Tian, Y., Cheng, W., & Jing, H. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s405020 · Cited by 74
UFL1 ablation in T cells suppresses PD-1 UFMylation to enhance anti-tumor immunity
He, C., Xing, X., Chen, H.-Y., Gao, M., Shi, J., Xiang, B., Xiao, X., Sun, Y., Yu, H., Xu, G., et al. (2024) · Molecular Cell · doi:10.1016/j.molcel.2024.01.024 · Cited by 75
Recent progress in stimuli-responsive nanosystems for inducing immunogenic cell death
Banstola, A., Poudel, K., Kim, J. O., Jeong, J., & Yook, S. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.07.038 · Cited by 71
In Situ Separable Nanovaccines with Stealthy Bioadhesive Capability for Durable Cancer Immunotherapy
Liu, Y., Yu, M., Chen, W., Sun, S., Huang, W., Wang, T., Peng, Z., Luo, Z., Fang, Y., Li, Y., et al. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.2c12986 · Cited by 72
Shin, J. M., Lee, C., Son, S., Kim, C. H., Lee, J. A., Ko, H., Shin, S., Song, S. H., Park, S., Bae, J., et al. (2021) · Advanced Science · doi:10.1002/advs.202103245 · Cited by 68
The effects of age and systemic metabolism on anti-tumor T cell responses
Drijvers, J. M., Sharpe, A. H., & Haigis, M. C. (2020) · eLife · doi:10.7554/elife.62420 · Cited by 69
“tomical location or tissue of origin (Boyiadzis et al., 2018; Waldman et al., 2020).”
BackgroundSPP1 + macrophages cause exhaustion of tumor-specific T cells in liver metastases
Trehan, R., Huang, P., Zhu, X. B., Wang, X., Soliman, M., Strepay, D., Nur, A., Kedei, N., Arhin, M., Ghabra, S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59529-0 · Cited by 74
Pan, C., Yang, H., Lu, Y., Hu, S., Wu, Y., He, Q., & Dong, X. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113170 · Cited by 72
Chen, P. P., Cepika, A., Agarwal, R., Saini, G., Uyeda, M. J., Louis, D. M., Cieniewicz, B., Narula, M., Amaya, L., Harre, N., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abf5264 · Cited by 68
Dias, A. M. M., Courteau, A., Bellaye, P., Kohli, É., Oudot, A., Doulain, P., Petitot, C., WALKER, P. M., Decréau, R. A., & Collin, B. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14112388 · Cited by 80
Yang, F., Zhang, D., Jiang, H., Ye, J., Zhang, L., Bagley, S. J., Winkler, J. D., Gong, Y., & Fan, Y. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abq3558 · Cited by 70
Two‐Photon Absorption Induced Cancer Immunotherapy Using Covalent Organic Frameworks
Yang, L., Zhang, L., Wan, S., Wang, S., Wu, Z., Yang, Q., Xiao, Y., Deng, H., & Sun, Z. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202103056 · Cited by 68
Jiang, H., Li, A. M., & Ye, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1004978 · Cited by 69
Wan, J., Ren, L., Li, X., He, S., Fu, Y., Xu, P., Meng, F., Xian, S., Pu, K., & Wang, H. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2210385120 · Cited by 67
Hypoxia-inducible factor in cancer: from pathway regulation to therapeutic opportunity
Ortmann, B. M. (2024) · BMJ Oncology · doi:10.1136/bmjonc-2023-000154 · Cited by 67
Zhou, F., Gao, J., Tang, Y., Zou, Z., Jiao, S., Zhou, Z., Xu, H., Xu, Z. P., Yu, H., & Xu, Z. (2021) · Advanced Materials · doi:10.1002/adma.202102668 · Cited by 67
Recent applications of quantitative systems pharmacology and machine learning models across diseases
Aghamiri, S. S., Amin, R., & Helikar, T. (2021) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-021-09790-9 · Cited by 67
CRISPR/Cas9 ribonucleoprotein-mediated genome and epigenome editing in mammalian cells
Bloomer, H., Khirallah, J., Li, Y., & Xu, Q. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114087 · Cited by 75
Gordon, K. S., Kyung, T., Perez, C. R., Holec, P. V., Ramos, A., Zhang, A. Q., Agarwal, Y., Liu, Y., Koch, C. E., Starchenko, A., et al. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00896-0 · Cited by 68
Balance between immunoregulatory B cells and plasma cells drives pancreatic tumor immunity
Mirlekar, B., Wang, Y., Li, S., Zhou, M., Entwistle, S., Buysscher, T. D., Morrison, A. B., Herrera, G., Harris, C., Vincent, B. G., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100744 · Cited by 74
Mathematical modeling of cancer immunotherapy for personalized clinical translation
Butner, J. D., Dogra, P., Chung, C. D., Pasqualini, R., Arap, W., Lowengrub, J. S., Vittorio Cristini, C., & Wang, Z. (2022) · Nature Computational Science · doi:10.1038/s43588-022-00377-z · Cited by 71
Uribe‐Herranz, M., Beghi, S., Ruella, M., Parvathaneni, K., Salaris, S., Κωστόπουλος, Ν., George, S. S., Pierini, S., Krimitza, E., Costabile, F., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.01.012 · Cited by 68
Biology-driven therapy advances in high-grade serous ovarian cancer
Wang, Y., Duval, A. J., Adli, M., & Matei, D. E. (2024) · Journal of Clinical Investigation · doi:10.1172/jci174013 · Cited by 74
Lin, F., Yin, S., Zhang, Z., Yu, Y., Fang, H., Liang, Z., Zhu, R., Zhou, H., Li, J., Cao, K., et al. (2024) · Cell · doi:10.1016/j.cell.2024.10.016 · Cited by 72
Adaptive immunity at the crossroads of autophagy and metabolism
Metur, S. P., & Klionsky, D. J. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00662-3 · Cited by 67
Cancer Associated Fibroblasts - An Impediment to Effective Anti-Cancer T Cell Immunity
Koppensteiner, L., Mathieson, L., O’Connor, R. A., & Akram, A. R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.887380 · Cited by 69
Prognostic significance of spatial and density analysis of T lymphocytes in colorectal cancer
Elomaa, H., Ahtiainen, M., Väyrynen, S. A., Ogino, S., Nowak, J. A., Friman, M., Helminen, O., Wirta, E., Seppälä, T. T., Böhm, J., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01822-6 · Cited by 67
Zheng, M., Zhang, W., Chen, X., Guo, H., Wu, H., Xu, Y., He, Q., Ding, L., & Yang, B. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.10.027 · Cited by 68
Wang, Y., Zhou, S., Wang, Y., Lu, Z.-D., Zhang, Y., Xu, C., & Wang, J. (2023) · Nature Communications · doi:10.1038/s41467-023-37656-w · Cited by 67
Immunotherapy for Metastatic Triple Negative Breast Cancer: Current Paradigm and Future Approaches
Geurts, V. C. M., & Kok, M. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01069-0 · Cited by 71
A T Cell‐Engaging Tumor Organoid Platform for Pancreatic Cancer Immunotherapy
Zhou, Z., der Jeught, K. V., Li, Y., Sharma, S., Yu, T., Moulana, I., Liu, S., Wan, J., Territo, P. R., Opyrchal, M., et al. (2023) · Advanced Science · doi:10.1002/advs.202300548 · Cited by 65
Lipid‐based nanoparticles as drug delivery systems for cancer immunotherapy
Hao, Y., Ji, Z., Zhou, H., Wu, D., Gu, Z., Wang, D., & ten Dijke, P. (2023) · MedComm · doi:10.1002/mco2.339 · Cited by 71
Oxygen‐driven cuproptosis synergizes with radiotherapy to potentiate tumor immunotherapy
Pei, P., Wang, Y., Shen, W., He, Q., Han, X., Zhang, C., Xie, Y., Zhou, G., Zhao, Y., Hu, L. T., et al. (2024) · Aggregate · doi:10.1002/agt2.484 · Cited by 66
Vara, B., Levi, S. M., Achab, A., Candito, D. A., Fradera, X., Lesburg, C. A., Kawamura, S., Lacey, B. M., Lim, J., Methot, J. L., et al. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.1c00096 · Cited by 65
Lima‐Sousa, R., Melo, B. L., Alves, C. G., Moreira, A. F., Mendonça, A., Correia, I. J., & de Melo‐Diogo, D. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202010777 · Cited by 65
Immunotherapy in Pancreatic Adenocarcinoma: Beyond “Copy/Paste”
Hester, R., Mazur, P. K., & McAllister, F. M. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0900 · Cited by 67
Recent advances in biomaterial-boosted adoptive cell therapy
Xue, Y., Che, J., Ji, X., Li, Y., Xie, J., & Chen, X. S. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00786f · Cited by 70
It’s Getting Complicated—A Fresh Look at p53-MDM2-ARF Triangle in Tumorigenesis and Cancer Therapy
Kung, C.-P., & Weber, J. D. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.818744 · Cited by 71
Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies
Motzer, R. J., Taylor, M. H., Evans, T. R. J., Okusaka, T., Glen, H., Lubiniecki, G. M., Dutcus, C. E., Smith, A. D., Okpara, C. E., Hussein, Z., et al. (2022) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2039123 · Cited by 65
Progress in advanced nanotherapeutics for enhanced photodynamic immunotherapy of tumor
Xiao, W., Song, M., Jiang, G., Liang, M., Chen, C., Yang, Z., & Zou, L. (2022) · Theranostics · doi:10.7150/thno.73566 · Cited by 68
Jin, J., Mu, Y., Zhang, H., Sturmlechner, I., Wang, C., Jadhav, R. R., Xia, Q., Weyand, C. M., & Goronzy, J. J. (2023) · Nature Aging · doi:10.1038/s43587-023-00399-w · Cited by 66
Gut microbiome for predicting immune checkpoint blockade-associated adverse events
Hu, M., Lin, X., Sun, T., Shao, X., Huang, X., Du, W., Guo, M., Zhu, X., Zhou, Y., Tong, T., et al. (2024) · Genome Medicine · doi:10.1186/s13073-024-01285-9 · Cited by 72
IRGQ-mediated autophagy in MHC class I quality control promotes tumor immune evasion
Herhaus, L., Mato, U. G., Eapen, V. V., Mačinković, I., Bailey, H., Prieto‐Garcia, C., Misra, M., Jacomin, A., Ammanath, A. V., Bagarić, I., et al. (2024) · Cell · doi:10.1016/j.cell.2024.09.048 · Cited by 71
Leptin, Both Bad and Good Actor in Cancer
Jiménez‐Cortegana, C., López-Saavedra, A., Sánchez-Jiménez, F., Pérez‐Pérez, A., Castiñeiras, J., Virizuela-Echaburu, J. A., de la Cruz‐Merino, L., & Sánchez‐Margalet, V. (2021) · Biomolecules · doi:10.3390/biom11060913 · Cited by 69
Microneedles in Action: Microneedling and Microneedles-Assisted Transdermal Delivery
Lim, D., & Kim, H.-J. (2022) · Polymers · doi:10.3390/polym14081608 · Cited by 64
Therapeutic cancer vaccines revamping: technology advancements and pitfalls
Antonarelli, G., Corti, C., Tarantino, P., Ascione, L., Cortés, J., Romero, P. J., Mittendorf, E., Disis, M. L., & Curigliano, G. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.08.2153 · Cited by 64
Shared genetic and epigenetic changes link aging and cancer
Zabransky, D. J., Jaffee, E. M., & Weeraratna, A. T. (2022) · Trends in Cell Biology · doi:10.1016/j.tcb.2022.01.004 · Cited by 67
A bispecific nanomodulator to potentiate photothermal cancer immunotherapy
Zhou, L., Feng, B., Wang, H., Wang, D., & Li, Y. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101466 · Cited by 63
Zetrini, A., Lip, H., Abbasi, A. Z., Alradwan, I. A., Ahmed, T., He, C., Henderson, J. T., Rauth, A. M., & Wu, X. Y. (2023) · Research · doi:10.34133/research.0247 · Cited by 64
Mian, S. A., Anjos‐Afonso, F., & Bonnet, D. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.619236 · Cited by 62
Metadata
- Authors
- Waldman, A. D., Fritz, J. M., & Lenardo, M. J.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Lenardo, Michael J.
- Venue
- Nature Reviews Immunology
- Published
- 2020-05-20
- Volume
- 20
- Issue
- 11
- Pages
- 651-668
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- PMC
- PMC7238960
- OpenAlex
- W3028523516
- Cited by
- 4,154
- References
- 302
- Citations by year
- 2026: 382 · 2025: 748 · 2024: 867 · 2023: 824 · 2022: 754 · 2021: 511 · 2020: 59
- FWCI
- 58.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Nature reviews. Immunology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases
- Emory University
- National Institutes of Health
- National Institute of General Medical Sciences (T32GM008169)
- National Institute of Allergy and Infectious Diseases
- NHLBI Division of Intramural Research
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- cancer immunotherapy, T cells, T cell regulation, immune checkpoint blockade, adoptive cellular therapy, clinical trials, immunotherapy toxicity, history of cancer immunotherapy
- MeSH terms
- Immune Checkpoint Inhibitors, Animals, Clinical Trials as Topic, Humans, Immunotherapy, Neoplasms, T-Lymphocytes, Immunotherapy, Adoptive, Cancer Vaccines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
